Novo Nordisk inks $2.1B oral obesity drug deal / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance

Gubra plots Roivant-like model as partnered obesity drugs take flight

3 days / endpoints / Kyle LaHucik

Pfizer gets obesity drug approval in China shortly after buying local rights

10 days / endpoints / Elizabeth Cairns

Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

11 days / medicalxpress

Roche partner Zealand posts Phase 2 data for amylin obesity drug

11 days / endpoints / Kyle LaHucik

Novo Nordisk details Irish expansion; EuroAPI’s challenges continue

11 days / endpoints / Anna Brown

What to know about how GLP-1 medications might fight addiction

11 days / medicalxpress

Twenty percent of eligible youth prescribed GLP-1 receptor agonists

12 days / medicalxpress

GLP-1 medications get at the heart of addiction, study finds

12 days / medicalxpress

Quitting GLP-1 drugs triggers rapid regain, but 25% of weight loss may last

12 days / medicalxpress

Eli Lilly launches its direct-to-employer platform for obesity drugs

12 days / fiercehealthcare

Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds

12 days / nytimes / Roni Caryn Rabin

AHA urges HHS to block Novo Nordisk’s 340B data demand

12 days / beckershospitalreview / Paige Twenter

FDA sends Novo Nordisk 2nd warning over GLP-1 ads

12 days / beckershospitalreview / Erica Cerutti

How gut bacteria and diet can reprogram fat to burn more energy

12 days / medicalxpress

No more weekly injections? How lettuce cells could deliver GLP-1 pills

12 days / medicalxpress

GLP-1 weight-loss drugs comparably effective across age, race and starting weight

12 days / medicalxpress

FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters

13 days / fiercehealthcare

FDA warns 30 telehealth firms over compounded GLP-1 claims

13 days / beckershospitalreview / Ella Jeffries

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

13 days / endpoints / Shelby Livingston

Novo Nordisk inks $2.1B oral obesity drug deal

14 days / beckershospitalreview / Ella Jeffries

Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds

19 days / medcitynews / Frank Vinluan

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

19 days / endpoints / Kyle LaHucik

Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 22 stories in 13 days

Related Stories

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 3 months
Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 3 months
Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 18 days
JP Morgan Healthcare Conference 2026: Pharma, AI, and Innovation Highlights / 1 month
Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 2 months
Pfizer Triumphs in $10B Metsera Bidding War / 4 months
Pfizer vs Novo Nordisk in Battle for Metsera Takeover / 4 months

Related Tags

Obesity

Novo Nordisk and Hims bury the hatchet and carve a deal (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (8 days)

GLP‑1 drugs associated with lower addiction risk in large study (10 days)

Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)

more #healthcare

Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (20 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (32 hrs)

more #pharmaceuticals

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.